Dec 20, 2021 7:00am EST Liver Cancer Patient Treated with Can-Fite’s Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study
Dec 07, 2021 7:00am EST Can-Fite’s Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in January; Topline Data Expected Q1 2022
Nov 26, 2021 7:00am EST Can-Fite Reports Third Quarter 2021 Financial Results & Provides Clinical Update
Nov 24, 2021 7:00am EST Can-Fite CEO Dr. Pnina Fishman to be Guest Speaker at 5th Annual NASH Summit 2021
Nov 23, 2021 7:00am EST Can-Fite’s Piclidenoson Commences Clinical Study for the Treatment of Canine Osteoarthritis
Nov 01, 2021 7:00am EDT Can-Fite’s Findings on Cannabis Compound’s Inhibition of Liver Cancer are Published in HEPATOLOGY and will be Presented at the AASLD’s The Liver Meeting® 2021 Conference
Oct 26, 2021 7:00am EDT Can-Fite CEO to Present Namodenoson’s Clinical Trial Data as Expert Speaker at 5th Annual Antifibrotic Drug Development Summit
Oct 21, 2021 7:00am EDT Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal
